Fig. 1: Study design (Part A reported here).

ATM ataxia–telangiectasia-mutated kinase, DLX dose level X, NSCLC non-small-cell lung cancer, Q3W every 3 weeks, RECIST response evaluation criteria in solid tumours, SCLC small-cell lung cancer, TNBC triple-negative breast cancer, WT wild type.